Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC and EH301 With Riluzole in ALS
NCT07414212Phase 2Recruiting
- Sponsor
- Biogipuzkoa Health Research Institute
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Acetylcysteine + EH301 with Placebo (2 arms). Primary endpoint: ALS Functional Rating Scale-Revised at 48 weeks. Started Nov 2025; status: recruiting.
02
Drugs
acetylcysteinenicotinamide riboside + pterostilbene
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07414212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414212.